Financial Data and Key Metrics Changes - For the full year 2025, consolidated EBITDA was reported at $307 million, slightly down from $311 million in 2024, while adjusted EBITDA improved by $40 million year-over-year to $293 million compared to $253 million in 2024 [7][15] - In the fourth quarter of 2025, consolidated EBITDA was $77 million, an increase from $72 million in the same quarter of the previous year [15] Business Line Data and Key Metrics Changes - The Expedited Freight segment reported EBITDA of $25 million in Q4 2025, up from $18 million a year ago, with a margin increase of 350 basis points to 10.1% [17] - The Omni Logistics segment achieved a reported EBITDA of $36 million in Q4 2025, compared to $32 million in Q4 2024, with a margin improvement to 10% from 9.8% [18] - The Intermodal segment's EBITDA was $7 million in Q4 2025, down from $10 million a year ago, with a margin of 14.2% compared to 17.5% in Q4 2024 [19] Market Data and Key Metrics Changes - The company noted a challenging environment in the Intermodal market, particularly with port activity, leading to declining shipments and revenue per shipment [19] - Cash generated from operating activities improved significantly, with $44 million generated in 2025 compared to a cash consumption of $69 million in 2024, marking a $113 million year-over-year improvement [20][24] Company Strategy and Development Direction - The company is focused on profitable long-term growth through the expansion of synergistic service offerings and enhancing customer value [11] - A key initiative is the One ERP project aimed at consolidating multiple financial systems into a single integrated platform to improve efficiency [12] - The company is also prioritizing customer service, strong leadership, and careful cost management to position itself for long-term success [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about a potential recovery in the freight environment, although they noted no significant positive signs at the end of 2025 [24] - The management team emphasized the importance of operational flexibility and the ability to add capacity quickly in response to market changes [32] Other Important Information - The company has made significant progress in its strategic alternatives review process and is nearing a conclusion [6] - The company has rebuilt its management team, adding experienced leaders to drive growth and success [11][12] Q&A Session Summary Question: How does the model perform in a recovery scenario? - Management indicated that the company has historically outperformed the industry in recovery scenarios due to its flexible operating model [32] Question: What is the outlook for the Omni segment's midterm margins? - Management noted that the diverse portfolio within the Omni segment allows for organic growth and margin stability across different service offerings [36] Question: Are customers sounding more upbeat given recent market trends? - Management reported consistent customer experiences and transparency, which has fostered comfort and loyalty among clients [47] Question: What is the update on the strategic review process? - Management confirmed that they are nearing a conclusion on the strategic alternatives review but could not provide further details [58] Question: What are the expectations for cash flow and CapEx in the coming year? - Management indicated that they expect to maintain a similar level of CapEx as a percentage of revenue while focusing on improving cash generation [63]

Core Viewpoint - Neuphoria Therapeutics Inc. is conducting a strategic alternatives review process to maximize value for stockholders, while responding to a revised acquisition proposal from Lynx1 Master Fund LP, which the Company believes undervalues its assets [1][4][5]. Strategic Review Process - The Board, with independent advisors, is engaged in a comprehensive review of strategic alternatives to enhance stockholder value, pausing R&D expenditures for BNC210 in PTSD during this evaluation [2][3]. - The strategic review process has attracted significant interest from various potential counterparties, with several parties already engaged under confidentiality agreements [2][3]. Lynx1's Proposal - Lynx1's revised bid of $4.75 per share is considered inadequate as it does not provide a meaningful premium and is close to the estimated cash value of the Company [4][5]. - The Board asserts that Lynx1's proposal fails to account for the value of existing licensing agreements that have generated substantial revenue and have potential for future payments [4][8]. Board's Position - The Company emphasizes that it will not pursue any transaction that undervalues its assets or disrupts the ongoing strategic review process, despite receiving multiple competing offers [5][10]. - The Board is committed to evaluating all proposals, including Lynx1's, but will prioritize those that align with the Company's long-term value [5][10]. Risks of Lynx1's Nominees - Electing Lynx1's nominees could compromise the Board's ability to objectively assess all proposals, potentially leading to the neglect of superior strategic opportunities [6][7]. - The Company urges stockholders to support its existing Board nominees to ensure the protection and maximization of value for all stockholders [7][11]. Company Overview - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders, with its lead candidate BNC210 aimed at treating PTSD [13]. - Following the AFFIRM-1 Phase 3 trial results, which missed primary and secondary endpoints, the Company has halted development of BNC210 in social anxiety disorder and is actively conducting a strategic review [13].

Core Viewpoint - Neuphoria Therapeutics Inc. is conducting a strategic alternatives review process to maximize value for stockholders, while responding to a revised acquisition proposal from Lynx1 Master Fund LP, which the Company believes undervalues its assets [1][4][5]. Strategic Review Process - The Board, with independent advisors, is engaged in a comprehensive review of strategic alternatives to enhance stockholder value, pausing R&D expenditures for BNC210 in PTSD during this evaluation [2][3]. - The strategic review process has attracted significant interest from various potential counterparties, with several parties already engaged under confidentiality agreements [2][3]. Lynx1's Proposal - Lynx1's revised bid of $4.75 per share is considered inadequate as it does not provide a meaningful premium and is close to the estimated cash value of the Company [4][5]. - The Board asserts that Lynx1's proposal fails to account for the value of Neuphoria's licensing agreements, which have generated tens of millions in revenue and have potential for future payments [4][8]. Board's Position - The Company emphasizes that it will not pursue any transaction that undervalues its assets or disrupts the ongoing strategic review process, despite receiving multiple competing offers [5][10]. - The Board urges stockholders to support its nominees to ensure an objective evaluation of all proposals and to protect stockholder value [7][11]. Due Diligence Concerns - Lynx1 is criticized for not conducting sufficient due diligence, leading to a proposal that significantly undervalues the Company's potential based on its existing contractual arrangements [8][9]. - The Company maintains that it is treating all interested parties fairly and equally in the strategic review process, countering Lynx1's claims of seeking special treatment [9][10].

Financial Data and Key Metrics Changes - The company reported consolidated EBITDA of $78 million for the third quarter of 2025, consistent with the $77 million reported in the second quarter of 2025 [12] - Adjusted EBITDA was $75 million, compared to $74 million in the second quarter of 2025 and $76 million in the third quarter of 2024 [14] - Cash provided by operations increased to $53 million in the third quarter of 2025, up from $51 million in the same quarter last year [18] Business Line Data and Key Metrics Changes - The Expedited Freight segment reported EBITDA of $30 million with a margin of 11.5%, maintaining the same EBITDA as the previous quarter but showing an improvement in margin from 10.4% a year ago [15] - The Omni Logistics segment achieved revenue of $340 million and reported EBITDA of $33 million, a 22% increase from $27 million in the third quarter of 2024 [16] - The Intermodal segment reported EBITDA of $8 million, consistent with the previous quarter and the same quarter last year [17] Market Data and Key Metrics Changes - The company noted a decline in tonnage but improved pricing programs and managed discretionary expenses effectively [15] - The overall freight environment remains challenging, with the company focusing on maintaining the right freight mix at optimal prices [15] Company Strategy and Development Direction - The company is undergoing a strategic alternatives review process, exploring potential sales, mergers, or other transactions to maximize long-term value [6][8] - The transformation plan aims to unify operations under a new regional structure, creating the OneGround network to enhance efficiency and collaboration [10][11] - The company is rationalizing its technology stack to improve efficiencies and drive cost savings [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism that market conditions will eventually rebound, emphasizing the importance of maintaining momentum in their progress [13] - The company remains focused on delivering industry-leading service quality while managing costs prudently [13] - Management highlighted the strength of the team and the solid foundation built for sustainable long-term growth despite macroeconomic uncertainties [23] Other Important Information - The company reported a total liquidity of $413 million at the end of the third quarter, an increase from $368 million at the end of the second quarter [19] - The credit agreement allows for the inclusion of unrealized and proforma savings in historical consolidated EBITDA, which has been adjusted for prior quarters [18] Q&A Session Summary Question: Update on Omni business and long-term margin targets - Management noted that the Omni business has shown stability in EBITDA margins, but optimal margins are currently suppressed due to the overall market conditions [26][28] Question: Commentary on seasonality in the business - Management indicated that the Omni segment is not expected to be highly seasonal due to the stability of the warehouse side of the business [32][34] Question: Update on LTL segment and cost realignment - Management emphasized that the company operates a variable-cost network, allowing for flexibility in adjusting costs based on volume [40][42] Question: Clarification on the strategic alternatives review process - Management reiterated that the review process is ongoing and that they will provide updates when appropriate [46][52] Question: Insights on cash flow and debt payments - Management explained that cash flow management is crucial, especially around semiannual debt payments, and they aim to generate more cash in the quarters leading up to those payments [56][58] Question: Benefits of the combined company and operational synergies - Management confirmed that the combination of the companies has been beneficial, allowing for growth and operational efficiency across segments [63][67]